NEOL has a colorful recent history to put it mildly. A search through the SEC filings after the the CEO was fired and the founder and COB was demoted can give you a taste of things. The first replacement CEO had a good looking resume - and was a dud rushed into fill a gap. The current CEO is untested.
Everything currently is riding on IL-13 beating the Gliadel Wafer in treating glioblastomas. Doesn't seem a great challenge but you never know. Will the market like a go-ahead rather than an early unblinding? I haven't the foggiest notion.
Critical for the future is the liposome technology but if you are short term trader, the liposomes probably don't matter.
Somehow the company has attracted hefty institutional interest and has been able to raise prodigious funds despite an erratic management. Somebody Up There must love the IL-13 and its delivery method.
http://biz.yahoo.com/bw/051121/20051121005425.html?.v=1 >> The timing for notification of meeting the PRECISE trial criterion for the second futility analysis is beyond our original projections and may be evident of greater extended survival than originally assumed for patients receiving cintredekin besudotox compared to GLIADEL® Wafer in the study," said Guillermo A. Herrera, NeoPharm's President and CEO. <<
These kinds of statements make the lawyers start salivating.
News 
Market Data 
Discover 
AI
